Quest Diagnostics Inc. (DGX) Releases FY13 Earnings Guidance
Quest Diagnostics Inc. (NYSE:DGX) issued an update on its FY13 earnings guidance on Thursday morning. The company provided EPS guidance of $3.85-3.95 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.17, Analyst RN reports. The company issued revenue guidance of -3.5% to ~$7.12 billion, compared to the consensus revenue estimate of $7.20 billion.
Shares of Quest Diagnostics Inc. (NYSE:DGX) opened at 58.75 on Thursday. Quest Diagnostics Inc. has a 1-year low of $55.16 and a 1-year high of $63.40. The stock has a 50-day moving average of $60.91 and a 200-day moving average of $59.78. The company has a market cap of $8.923 billion and a P/E ratio of 17.93.
Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings results on Thursday, October 17th. The company reported $1.02 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.20 by $0.18. The company had revenue of $1.79 billion for the quarter, compared to the consensus estimate of $1.84 billion. During the same quarter in the prior year, the company posted $1.18 earnings per share. The company’s quarterly revenue was down 1.9% on a year-over-year basis. Analysts expect that Quest Diagnostics Inc. will post $4.23 EPS for the current fiscal year.
A number of research firms have recently commented on DGX. Analysts at Citigroup Inc. reiterated a neutral rating on shares of Quest Diagnostics in a research note to investors on Friday, October 11th. They now have a $60.00 price target on the stock, down previously from $64.00. On a related note, analysts at Wells Fargo & Co. reiterated a market perform rating on shares of Quest Diagnostics in a research note to investors on Thursday, October 10th. Finally, analysts at Zacks reiterated a neutral rating on shares of Quest Diagnostics in a research note to investors on Tuesday, October 8th. They now have a $65.00 price target on the stock. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and five have issued a buy rating to the company. Quest Diagnostics currently has an average rating of Hold and a consensus target price of $61.31.
Quest Diagnostics Incorporated (NYSE:DGX)is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.